Ribosomal Protein L13A Inhibitors
The class of compounds identified as Ribosomal Protein L13A Inhibitors includes a diverse range of molecules primarily targeting protein synthesis at various stages. These compounds do not interact directly with Ribosomal Protein L13A but exert their influence through the disruption of broader processes within which L13A functions. This includes the inhibition of ribosomal assembly, the elongation phase of protein synthesis, or cellular signaling pathways related to protein synthesis. For example, molecules like Cycloheximide and Emetine are known to inhibit eukaryotic protein synthesis, thereby impacting the functional integration of L13A into the ribosome.
Additionally, compounds such as Ricin and Puromycin specifically target the ribosomal RNA and the translation process, respectively. Their action can lead to a compromised ribosomal structure or function, which in turn can affect the role of L13A within the ribosome. Inhibitors like Rapamycin, acting on cellular signaling pathways such as mTOR, indirectly influence the protein synthesis machinery, and thus the role of L13A. The diversity in the action of these compounds reflects the complex nature of ribosomal function and the multiple steps at which protein synthesis can be regulated or disrupted.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
This chemical is a known inhibitor of vacuolar-type H+-ATPase (V-ATPase). By inhibiting this enzyme, it prevents the acidification of organelles, a necessary step in the autophagy process where CALCOCO2 is involved. | ||||||
Autophagy Inhibitor, 3-MA | 5142-23-4 | sc-205596 sc-205596A | 50 mg 500 mg | $65.00 $261.00 | 113 | |
As a class III PI3K inhibitor, 3-Methyladenine can inhibit autophagy initiation. Since CALCOCO2 is involved in later stages of autophagy, this indirect inhibition can affect its function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent PI3K inhibitor. By inhibiting PI3K, which is involved in the autophagy pathway, it can indirectly influence the function of CALCOCO2. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Chloroquine works by inhibiting the fusion of autophagosomes and lysosomes, preventing the completion of autophagy process, thus indirectly affecting CALCOCO2's role. | ||||||
Spautin-1 | 1262888-28-7 | sc-507306 | 10 mg | $168.00 | ||
Spautin-1 promotes the degradation of certain autophagy proteins, potentially indirectly affecting the role of CALCOCO2 in autophagy. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 is another PI3K inhibitor. Given the role of PI3K in initiating autophagy, its inhibition can indirectly affect the functionality of CALCOCO2. | ||||||
Concanamycin A | 80890-47-7 | sc-202111 sc-202111A sc-202111B sc-202111C | 50 µg 200 µg 1 mg 5 mg | $66.00 $167.00 $673.00 $2601.00 | 109 | |
Like Bafilomycin A1, Concanamycin A is a V-ATPase inhibitor, disrupting autophagy by preventing organelle acidification. | ||||||
SAR405 | 1523406-39-4 | sc-507416 | 1 mg | $125.00 | ||
SAR405 is a specific inhibitor of PIK3C3/Vps34, an important part of the autophagy pathway, thus can indirectly affect CALCOCO2 activity. | ||||||
Niclosamide | 50-65-7 | sc-250564 sc-250564A sc-250564B sc-250564C sc-250564D sc-250564E | 100 mg 1 g 10 g 100 g 1 kg 5 kg | $38.00 $79.00 $188.00 $520.00 $1248.00 $5930.00 | 8 | |
Niclosamide has been shown to disrupt the process of autophagy, potentially influencing the functionality of CALCOCO2. | ||||||
PIK-III | 1383716-40-2 | sc-507530 | 5 mg | $170.00 | ||
PIK-III is a selective inhibitor of Vps34, thereby affecting the initiation of autophagy and potentially influencing CALCOCO2's role. | ||||||